Keytruda and Embolism - a phase IV clinical study of FDA data

Summary:

Embolism is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Cisplatin, and have Endometrial cancer.

The phase IV clinical study analyzes which people have Embolism when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Embolism?

Embolism (obstruction of an artery, typically by a clot of blood or an air bubble) is found to be associated with 721 drugs and 919 conditions by eHealthMe. Check the latest studies of Embolism.

On Jun, 16, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 26 people (0.05%) have Embolism.

Among these 26 people:

How long have people been on Keytruda when they have Embolism? *

What is the gender of people who have Embolism when taking Keytruda? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Embolism when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Embolism? *

Pulmonary Embolism (blockage of the main artery of the lung): 5 people, 19.23%
Type 1 Diabetes: 3 people, 11.54%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 3 people, 11.54%
High Blood Pressure: 3 people, 11.54%
Visual Acuity Reduced (reduced clearness of vision): 2 people, 7.69%
Pneumonia: 2 people, 7.69%
Impaired Healing: 2 people, 7.69%
Visual Field Defect: 2 people, 7.69%
Intestinal Infarction (intestinal tissue death): 2 people, 7.69%
Retinal Artery Thrombosis (blood clot in retinal artery): 2 people, 7.69%

What are the existing conditions these people have? *

Endometrial Cancer: 8 people, 30.77%
Oesophageal Carcinoma (cancer tumour of oesophagus): 4 people, 15.38%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 11.54%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 11.54%
Insomnia (sleeplessness): 3 people, 11.54%
Cough: 3 people, 11.54%
Constipation: 3 people, 11.54%
Lung Squamous Cell Carcinoma Stage Iv (the lung cancer has spread to the other lung, and/or to lymph nodes, fluid around the lungs or heart, and/or other places in the body, such as the brain, liver, adrenal glands, kidneys, or bones): 2 people, 7.69%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 1 person, 3.85%
Lung Squamous Cell Carcinoma Metastatic (lung squamous cell cancer spreads to other body part): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Embolism?

- Check whether Embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Embolism treatments and more:

Embolism (13,418 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism:

Embolism (721 drugs)

Browse all the conditions that are associated with Embolism:

Embolism (919 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.